

References

I-214

1. Reblozyl [package insert]. Summit, NJ: Celgene Corporation, November 2019.
2. Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β -thalassemia. *Blood*. 2019;133(12):1279-1289.
3. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Luspatercept.
4. Micromedex DrugDex Compendium®. 2020. Luspatercept.
5. Hayes, Inc. Hayes Emerging Technology Report. Reblozyl (Luspatercept) for Beta Thalassemia. Lansdale, PA: Hayes, Inc.; November, 2019.